Medline (MDLN) Stock Price Target 2026

The average analyst price target for Medline is $47, 15.8% above the current price. Of 23 analysts, 20 rate it Buy and 3 Hold. Targets range from $34 to $55. The latest change came on Nov 5, 2026, when UBS raised its price target on Medline from $43 to $49 and kept a Buy rating.

The Average Analyst Price Target for Medline is $47.

Price Target Range — 4 Quarters

Analyst Consensus — 23 Analysts

20Buy

3Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$47Upside to Avg. PT+15.8%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Medline Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 5, 2026	UBS	Kevin Caliendo	PT Raise	Buy	$43→$49
Nov 5, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$45→$47
Nov 5, 2026	Leerink Partners	Michael Cherny	PT Raise	Outperform	$43→$46
Nov 5, 2026	Evercore ISI Group	Elizabeth Anderson	PT Raise	Outperform	$38→$44
Nov 5, 2026	BTIG	David Larsen	Maintained	Buy	$55
Oct 22, 2026	Mizuho	Steven Valiquette	PT Cut	Outperform	$48→$45
Oct 9, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$45→$43
Sep 25, 2026	UBS	Kevin Caliendo	PT Cut	Buy	$45→$43
Aug 27, 2026	BTIG	David Larsen	Maintained	Buy	$55
Aug 12, 2026	JP Morgan	Lisa Gill	PT Cut	Overweight	$53→$46
Aug 11, 2026	Tigress Financial	Ivan Feinseth	PT Cut	Buy	$62→$55
Aug 11, 2026	Wells Fargo	Stephen Baxter	PT Cut	Equal-Weight	$45→$34
Aug 10, 2026	TD Cowen	Charles Rhyee	PT Cut	Buy	$53→$45
Aug 6, 2026	RBC Capital	Ryan Halsted	PT Cut	Outperform	$53→$46
Aug 6, 2026	Truist Securities	Jailendra Singh	PT Cut	Buy	$56→$47
Aug 6, 2026	Evercore ISI Group	Elizabeth Anderson	PT Cut	Outperform	$48→$39
Aug 6, 2026	Stifel	Rick Wise	PT Cut	Buy	$50→$45
Jul 31, 2026	BTIG	David Larsen	Maintained	Buy	$55
Jun 3, 2026	Baird	Eric Coldwell	PT Cut	Outperform	$57→$45
Jun 1, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$50→$45